CCRM
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

CCRM Trademark

Serial Number: 79338771 • Registration: 7226858

CCRM is a trademark filed by Centre for Commercialization of Regenerative Medicine on November 19, 2021. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Centre for Commercialization of Regenerative Medicine (3 trademarks)

661 University Avenue

Entity Type: 54

Trademark Details

Filing Date

November 19, 2021

Registration Date

November 28, 2023

Published for Opposition

September 12, 2023

Goods & Services

Reviewing standards and practices to assure compliance with regulations related to the research, development, manufacture and sale of products in the health care and medical fields and the administration of health care services

Custom manufacture of biotechnological products for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms

Development of pharmaceutical preparations and medicines; pharmaceutical research and development; research and development of new biotechnological products for others for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms; development of new biotechnological products for others for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms; providing medical and scientific research information in the field of clinical trials; medical and scientific research, namely, conducting clinical trials for others; genetic testing for scientific research purposes in the field of biotechnological products for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms; scientific research in the field of genetic engineering, namely, research of biotechnological products for therapeutic use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state or their symptoms

Business planning; providing market intelligence services

Filing History

LIMITATION OF GOODS RECEIVED FROM IB
Mar 19, 2026 LIMG
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 8, 2024 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Mar 2, 2024 XXSS
GENERIC MADRID TRANSACTION CREATED
Mar 2, 2024 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 28, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 28, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 28, 2023 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Oct 16, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 27, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 27, 2023 OPNR
NOTIFICATION PROCESSED BY IB
Sep 12, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 12, 2023 NPUB
PUBLISHED FOR OPPOSITION
Sep 12, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 23, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 23, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 23, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 8, 2023 CNSA
ASSIGNED TO EXAMINER
Jul 20, 2023 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 9, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 8, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 8, 2023 TROA
NEW REPRESENTATIVE AT IB RECEIVED
May 7, 2023 NREP
REFUSAL PROCESSED BY IB
Jan 4, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 9, 2022 RFCS
REFUSAL PROCESSED BY MPU
Dec 9, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 28, 2022 RFCR
NON-FINAL ACTION WRITTEN
Sep 27, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 31, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 26, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 22, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 21, 2022 REPR